ASCO 2026: Phase 3 RAS-Blocking Drug Results Could Transform Pancreatic Care

References

1. 1.American Society of Clinical Oncology. (2026). ASCO Annual Meeting Program. Journal of Clinical Oncology, 44(16_suppl). https://doi.org/10.1200/JCO.2026.44.16_suppl
2. 2.Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Ganji, K., Hibner, T., Kondo, S., Koyama, S., Lanman, B. A., Lawson, J., Limberakis, C., Liu, J., Lohman, J., Louie, R. J., Mathison, C. J., Mendonca, R., Mitchell, L., ... Lipford, J. R. (2019). The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature, 575(7781), 217-223. https://doi.org/10.1038/s41586-019-1694-1
3. 3.Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J. L., Gourgou-Bourgade, S., de la Fouchardière, C., Bennouna, J., Bachet, J. B., Khemissa-Akouz, F., Péré-Vergé, D., Delbaldo, C., Assenat, E., Chauffert, B., Michel, P., Montoto-Grillot, C., & Ducreux, M. (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New England Journal of Medicine, 364(19), 1817-1825. https://doi.org/10.1056/NEJMoa1011923
4. 4.Feuerstein, A. (2026). An ASCO preview: What to watch for at cancer research's big meeting. STAT News. https://www.statnews.com/2026/05/28/asco-preview-cancer-meeting/
5. 5.Mizrahi, J. D., Surana, R., Valle, J. W., & Shroff, R. T. (2020). Pancreatic cancer. The Lancet, 395(10242), 2008-2020. https://doi.org/10.1016/S0140-6736(20)30974-0
6. 6.Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013). K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature, 503(7477), 548-551. https://doi.org/10.1038/nature12796
7. 7.Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023). Cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 73(3), 233-254. https://doi.org/10.3322/caac.21763
8. 8.Waters, A. M., & Der, C. J. (2018). KRAS: The critical driver and therapeutic target for pancreatic cancer. Cold Spring Harbor Perspectives in Medicine, 8(12), a031435. https://doi.org/10.1101/cshperspect.a031435